An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

NCT04993261 | Active Not Recruiting Early Phase 1

• 2 other identifiers: 2014-0578NCI-2019-02477
• Study Type: interventional
• Target: 71
• Locations: 1 country
• Sites: 1

Brief Summary

This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors. CT is an imaging technique that uses x-rays and a computer to create images of areas inside the body. Dual energy computed tomography is a technique used during routine CT scans to help obtain and process the image after the scan is complete. Doctors want to learn if dual energy computed tomography can help improve the detection of carcinoid tumors during routine CT scans.

Conditions

Carcinoid Syndrome; Carcinoid Tumor; Digestive System Neuroendocrine Tumor G1; Metastatic Carcinoid Tumor

Outcome Measures

Primary Outcomes (1)

• Sensitivity and specificity of dual energy computed tomography in detecting primary gastrointestinal carcinoid tumors

  through study completion, an average of 1 year

Study Arms (1)

Diagnostic (dual energy CT scan)

EXPERIMENTAL

Patients undergo one dual energy CT scan during scheduled CT scan.

Procedure: Dual-Energy Computed Tomography

Interventions

Dual-Energy Computed Tomography PROCEDURE

Undergo dual energy CT scan

Also known as: DECT

Diagnostic (dual energy CT scan)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with: clinical features of carcinoid syndrome (or) increased serum and urinary markers suggestive of carcinoid (or) endoscopic biopsy proven carcinoid (or) metastases which are biopsy proven as carcinoid.
• Patient is scheduled to have a clinically indicated staging CT exam.
• Patients who have signed their informed consent form to undergo the study.

You may not qualify if:

• Patients who have already had their primary GI carcinoid resected.
• Contraindication to intravenous contrast agents (e.g. allergy, renal failure, dialysis, pregnancy etc.).
• Pregnant patients.

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead

Study Sites (1)

M D Anderson Cancer Center

Houston, Texas, 77030, United States

Location

MeSH Terms

Conditions

Serotonin Syndrome; Carcinoid Tumor

Condition Hierarchy (Ancestors)

Drug-Related Side Effects and Adverse Reactions; Chemically-Induced Disorders; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Officials

• Ajaykumar Morani

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 21, 2021
• First Posted: August 6, 2021
• Study Start: September 23, 2015
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: February 19, 2026

Record last verified: 2026-02

Locations

US (1)